Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy

• Published in: International journal of clinical oncology Vol. 16; no. 2; pp. 118 - 124
• Main Authors: Yakushijin, Yoshihiro, Shikata, Hisaharu, Takaoka, Ikue, Horikawa, Tamami, Takeuchi, Kazuhito, Yamanouchi, Jun, Azuma, Taichi, Narumi, Hiroshi, Hato, Takaaki, Yasukawa, Masaki
• Format: Journal Article
• Language: English
• Published: Japan Springer Japan 01.04.2011; Springer Nature B.V
• Subjects: Aged; Antibiotics, Antineoplastic - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Blood diseases; Cancer Research; Chemotherapy; Cost-benefit; Cost-Benefit Analysis; Cyclophosphamide - administration & dosage; Cyclophosphamide - adverse effects; Doxorubicin - administration & dosage; Doxorubicin - adverse effects; Drug Administration Schedule; Drug dosages; Drug therapy; Febrile neutropenia (FN); Female; Fever - blood; Fever - drug therapy; Granulocyte Colony-Stimulating Factor - administration & dosage; Granulocyte Colony-Stimulating Factor - economics; Granulocyte colony-stimulating factors (G-CSF); Health care expenditures; Humans; Lenograstim; Leukocytes - drug effects; Lymphoma; Lymphoma, Large B-Cell, Diffuse - blood; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - economics; Male; Medicine; Medicine & Public Health; Middle Aged; Neutropenia - blood; Neutropenia - drug therapy; Neutropenia - economics; Neutrophils - drug effects; Non-Hodgkin lymphoma (NHL); Oncology; Original Article; Prednisone - administration & dosage; Prednisone - adverse effects; R-CHOP; Recombinant Proteins - administration & dosage; Recombinant Proteins - economics; Risk factors; Surgical Oncology; Vincristine - administration & dosage; Vincristine - adverse effects; Granulocyte colony-stimulating factors (G-CSF); Cost-benefit; R-CHOP; Non-Hodgkin lymphoma (NHL); Febrile neutropenia (FN)
• ISSN: 1341-9625; 1437-7772; 1437-7772
• DOI: 10.1007/s10147-010-0134-x

Background In order to analyze the clinical activity and cost-effectiveness of granulocyte colony-stimulating factors (G-CSF), the prophylactic usage of G-CSF in patients treated with a single chemotherapy regimen during early courses was prospectively evaluated. Methods Thirty patients with newly diagnosed non-Hodgkin lymphoma (NHL) treated with the first course of an R-CHOP regimen were enrolled randomly. After treatment with the first course of chemotherapy, a daily dose of G-CSF (lenograstim, 100 μg) was administered to half (15 cases) of the patients, and a dose of G-CSF (100 μg) was administered every other day to the other half of the patients when leukocytopenia (<1.5 × 10 9 /L) and/or neutropenia (<0.5 × 10 9 /L) occurred. Changes in leukocyte and neutrophil counts, prophylaxis, febrile neutropenia (FN) events, and cost performance between the two groups were analyzed. Results No significant difference between the two groups was observed in recoveries of leukocyte and neutrophil counts and evidence of FN. The only difference was the total cost of G-CSF. Conclusion We concluded that every-other-day use of G-CSF was as clinically effective for the prophylaxis of FN as the daily use of G-CSF, and economically speaking, the administration of G-CSF every other day should be more beneficial for patients with NHL during early courses of R-CHOP chemotherapy.